R
Robert Ilaria
Researcher at Eli Lilly and Company
Publications - 26
Citations - 921
Robert Ilaria is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Tasisulam Sodium & Olaratumab. The author has an hindex of 11, co-authored 26 publications receiving 810 citations. Previous affiliations of Robert Ilaria include University of Texas Southwestern Medical Center & Celgene.
Papers
More filters
Journal ArticleDOI
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
William D. Tap,William D. Tap,Robin L. Jones,Robin L. Jones,Brian A. Van Tine,Bartosz Chmielowski,Anthony D. Elias,Douglas Adkins,Mark Agulnik,Matthew M. Cooney,Michael B. Livingston,Gregory K. Pennock,Meera Hameed,Gaurav D. Shah,Amy Qin,Ashwin Shahir,Damien M. Cronier,Robert Ilaria,Ilaria Conti,Jan Cosaert,Gary K. Schwartz +20 more
TL;DR: An open-label phase 1b and randomised phase 2 study of doxorubicin plus olaratumab treatment in patients with unresectable or metastatic soft-tissue sarcoma at 16 clinical sites in the USA, finding progression-free survival in phase 2 was 6.6 months and the efficacy was assessed.
Journal ArticleDOI
Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors.
Yeny Castillero-Trejo,Susan Eliazer,Lilin Xiang,James A. Richardson,Robert Ilaria,Robert Ilaria +5 more
TL;DR: In this article, conditions for the isolation and propagation of murine primary bone-derived cells (mPBDCs) that stably express EWS/FLI-1 were developed.
Journal ArticleDOI
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia.
Saroj Vadhan-Raj,Rafat Abonour,Jonathan W. Goldman,David Smith,Christopher A. Slapak,Robert Ilaria,Ramon V. Tiu,Xuejing Wang,Sophie Callies,Joanne Cox,Jay Tuttle,Yiu Keung Lau,Eric Roeland +12 more
TL;DR: The findings indicate that LY2787106 was well tolerated in cancer patients with anemia and that targeting the hepcidin-ferroportin pathway by neutralizing hePCidin resulted in transient iron mobilization, thus supporting the role of he pcidin in iron regulation.
Journal ArticleDOI
Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization.
Timothy I. Meier,Mark Uhlik,Sudhakar Chintharlapalli,Michele Dowless,Robert D. Van Horn,Julie Stewart,Wayne Blosser,James A. Cook,Debra A. Young,Xiang S. Ye,Glenn F. Evans,Kelly M. Credille,Darryl Ballard,Lysiane Huber,Andrew Capen,Marcio Chedid,Robert Ilaria,Michele C. Smith,Louis Stancato +18 more
TL;DR: Data show that tasisulam has a unique, dual-faceted mechanism of action involving mitotic catastrophe and antiangiogenesis, a phenotype distinct from conventional chemotherapies and published anticancer agents.
Journal ArticleDOI
Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
William P. McGuire,Richard T. Penson,Martin Gore,Antonio Casado Herraez,Patrick Peterson,Ashwin Shahir,Robert Ilaria +6 more
TL;DR: The addition of olaratumab to liposomal doxorubicin did not result in significant prolongation of PFS or OS in platinum-resistant or platinum-refractory ovarian cancer patients.